<DOC>
	<DOCNO>NCT00611637</DOCNO>
	<brief_summary>The purpose study determine safety feasibility CMV specific , T cell adoptive immunotherapy patient undergone allogeneic stem cell transplantation malignant disease .</brief_summary>
	<brief_title>CMV pp65 Specific T Cell Adoptive Immunotherapy Allogeneic Stem Cell Transplantation Malignant Disease</brief_title>
	<detailed_description>The primary purpose clinical trial evaluate safety treatment .</detailed_description>
	<criteria>Stratum 1 : Subjects must undergo nonmyeloablative stem cell transplant 6/6 match , sibling donor treatment malignancy Stratum 2 : Subjects must undergo nonmyeloablative stem cell transplant 3/6 , 4/6 , 5/6 match , sibling donor treatment malignancy . Stratum 3 : Subjects must undergo myeloablative stem cell transplant 3/6 , 4/6 , 5/6 match , sibling donor treatment malignancy . Donor must CMV seropositive . Karnofsky performance status â‰¥ 70 % . Subject donor must one follow HLA type : HLA A*0201 , HLAA*0101 , HLAA*2402 , HLAB*0702 , HLAB*0801 , HLAB*35 , HLADR*1 , HLADR*4 . Availability stem cell donor provide multiple PBMC sample Tcell culture need . These sample could obtain via 90cc peripheral blood draw leukapheresis . Stem cell donor must satisfy BMT Program criterion undergo leukapheresis provide DLI consent provide repeat leukapheresis necessary . Ability understand provide sign informed consent fulfills Institutional Review Board guideline . Ability return Duke University Medical Center adequate followup require protocol . In order receive T cell infusion , subject : At least 2 week time allogeneic stem cell transplant . Without Grade 3 4 , nonhematologic , major organ toxicity within precede 1 week ; non major organ toxicity must resolve grade2 less . Pregnant woman nurse mother . Current prior history brain metastasis . More 12 month since allogeneic stem cell reinfusion . HIV+ , Hepatitis BsAg+ , Hepatitis C Ab+</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Immunotherapy</keyword>
</DOC>